EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Share Price
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.16 USD | +4.28% |
|
+5.96% | +18.24% |
| Sales 2024 * | 6.56B 518B | Sales 2025 * | 7.2B 568B | Capitalization | 54.33B 4,287B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.62B 128B | Net income 2025 * | 1.86B 147B | EV / Sales 2024 * | 8.02 x |
| Net cash position 2024 * | 1.7B 134B | Net cash position 2025 * | 2.89B 228B | EV / Sales 2025 * | 7.14 x |
| P/E ratio 2024 * |
33.9
x | P/E ratio 2025 * |
29.3
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | +4.28% | ||
| 1 week | +5.96% | ||
| Current month | +6.48% | ||
| 1 month | +1.08% | ||
| 3 months | +4.79% | ||
| 6 months | +34.55% | ||
| Current year | +18.24% |
1 week
84.67
90.37
1 month
83.5090.37
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
13.02131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 31/12/14 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 31/12/13 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 04/07/16 |
| Chairman | 67 | 12/11/14 | |
Steven Loranger
BRD | Director/Board Member | 72 | 15/03/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 42 M€ | +2.62% | - | |
| 2.34% | 17 M€ | +7.35% | - | |
| 2.13% | 6 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/24 | 90.16 | +4.28% | 3,111,296 |
| 14/05/24 | 86.46 | +2.08% | 2,127,401 |
| 13/05/24 | 84.7 | -2.33% | 2,579,306 |
| 10/05/24 | 86.72 | -0.80% | 1,988,029 |
| 09/05/24 | 87.42 | +2.74% | 3,421,901 |
Delayed Quote Nyse, May 15, 2024 at 09:00 pm
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.16
USD
Average target price
95.9
USD
Spread / Average Target
+6.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.24% | 54.33B | |
| +12.85% | 229B | |
| +13.88% | 195B | |
| +18.39% | 142B | |
| +28.78% | 109B | |
| +2.40% | 64.85B | |
| +7.04% | 52.09B | |
| +10.83% | 45.15B | |
| +5.94% | 37.39B | |
| +28.26% | 32.41B |
- Stock Market
- Equities
- EW Stock
